C12Y 304/21035
Tissue kallikrein
Official title: Tissue kallikrein (3.4.21.35)
C12Y304/21035 (Tissue kallikrein) appears on 7 US grants and 23 published applications in this corpus.
Search patents in C12Y- Granted patents
- 7
- Published applications
- 23
- Assignees
- 12
- Inventors
- 50
- Latest grant
- 17 Jun 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 2 |
| 2014 | 0 | 1 |
| 2015 | 0 | 1 |
| 2016 | 1 | 0 |
| 2017 | 1 | 2 |
| 2018 | 1 | 0 |
| 2019 | 0 | 1 |
| 2020 | 0 | 1 |
| 2021 | 1 | 1 |
| 2022 | 0 | 2 |
| 2023 | 1 | 2 |
| 2024 | 1 | 2 |
| 2025 | 1 | 6 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Dosage forms of tissue kallikrein 117 Jun 2025US 12,329,805 B2DiaMedica Inc.
- Dosage forms of tissue kallikrein 12 Jan 2024US 11,857,608 B2DiaMedica Inc.
- Peptides inhibiting KLK1, KLK4, or KLK4 and KLK819 Dec 2023US 11,845,786 B2Daiichi Sankyo Company, Limited
- Peptides inhibiting KLK1, KLK4, or KLK4 and KLK828 Dec 2021US 11,208,467 B2Daiichi Sankyo Company, Limited
- Pegylated tissue kallikrein, and preparation method therefor and uses thereof21 Aug 2018US 10,052,368 B2Gensun Institute of Biomedicine Co., Ltd.
- Multiple biomarker for cancer diagnosis and use thereof26 Feb 2026US 2026/0055469 A1Maxion Corp.
- Dosage forms of tissue kallikrein 16 Nov 2025US 2025/0339500 A1DiaMedica Inc.
- Intravenous compositions of tissue kallikrein-1 and related methods16 Oct 2025US 2025/0319167 A1
- Tissue kallikrein-1 for treating pregnancy disorders31 Jul 2025US 2025/0242001 A1
- Anti-klk4 antibodies and uses thereof26 Jun 2025US 2025/0206846 A1Yeda Research and Development Co. Ltd.
Most cited
By later US patents
- Human tissue kallikrein 1 glycosylation isoforms4US 9,364,521 B2DiaMedica Inc. · 2016
- Human tissue kallikrein 1 glycosylation isoforms2US 9,839,678 B2DiaMedica Inc. · 2017
- Peptides inhibiting KLK1, KLK4, or KLK4 and KLK81US 11,208,467 B2Daiichi Sankyo Company, Limited · 2021
- Peptides inhibiting KLK1, KLK4, or KLK4 and KLK81US 11,845,786 B2Daiichi Sankyo Company, Limited · 2023
- Dosage forms of tissue kallikrein 11US 11,857,608 B2DiaMedica Inc. · 2024